Ignite Creation Date:
2024-05-06 @ 1:03 PM
Last Modification Date:
2024-10-26 @ 1:08 PM
Study NCT ID:
NCT03920540
Status:
COMPLETED
Last Update Posted:
2024-04-16
First Post:
2019-04-16
Brief Title:
A Study of GC1111 in Hunter Syndrom Patients
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
Phase 3 Double-blind Randomized Active-controlled Part 1 and Open-labeled Historical Placebo Controlled Part 2 Study to Evaluate the Efficacy of Hunterase Idursulfase-beta in Hunter Syndrome Mucopolysaccharidosis II Patients
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to evaluate the efficacy of GC1111 in Hunter Syndrome Patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None